Share this article on:

Corticosteroids

Isaksson, Marléne; Bruze, Magnus

Section Editor(s): BELSITO, DONALD V. MD

Contact Allergen of the Year

SECTION EDITOR:

Department of Dermatology

University of Kansas Medical Center

3901 Rainbow Blvd.

Kansas City, KS 66160-7319

Tel: 913-588-3840; Fax: 913-588-4060

E-mail: dbelsito@kumc.edu

From the Department of Occupational and Environmental Dermatology, Malmö University Hospital, Malmö, Sweden.

Reprints not available.

CORTICOSTEROIDS still constitute the main armamentarium for the symptomatic treatment of inflammatory skin diseases. One drawback that has been recognized during the last 10 to 15 years is hypersensitivity to these substances; delayed-type hypersensitivity is by far the most common, but type I allergy has also been observed. Routine patch testing with one or two corticosteroids in consecutively tested dermatitis patients has detected a fairly high frequency of hypersensitivity to corticosteroids after topical as well as systemic administration; figures of up to 5% have been presented.1-5 The three aspects of corticosteroid contact allergy that we wish to focus on here must be considered; otherwise, the risk of missing such allergy may be significantly increased.

Back to Top | Article Outline

Clinical Picture

The first issue is the clinical picture. Corticosteroid contact allergy is rarely suspected from the history of the patient or from the appearance of the dermatitis, which may be modified by the antiinflammatory action of the corticosteroid itself.6 Any patient with a long-standing nonhealing dermatitis (such as stasis dermatitis,7 atopic eczema, or chronic hand eczema) that has been treated with corticosteroids should at some time be investigated for corticosteroid allergy. A topically treated eczema may evolve into a chronic inflammatory skin lesion that may heal by itself if administration of the incriminating corticosteroid is stopped. Deterioration of a previous dermatitis, sometimes with spreading, may also be seen.8-13 However, reactions that are more acute (such as a genital edema with erythema and vesicles,14 erythema multiforme-like contact dermatitis,15 generalized rashes,16,17 angioedema of the face, and an acute oozing eczematous reaction after local corticosteroid treatment10) have also been reported.

Back to Top | Article Outline

Patch Testing

The second issue deals with patch testing. Corticosteroid markers should be present in any standard series in order to detect corticosteroid contact allergy because the clinical picture is not obviously one of a contact eczema. Unfortunately, more than one marker for corticosteroid contact allergy must be used because studies have shown that four groups of simultaneously reacting or crossreacting corticosteroids exist.18 Three screening markers for corticosteroid contact allergy are tixocortol pivalate (a marker for group A),1,2,18,19 budesonide (marker for group B),18,20,21 and hydrocortisone-17-butyrate (Hc-17-B),1,2,6,22,23 which together seem to detect the majority of patients who are allergic to corticosteroids.

Concerning the optimal patch-test preparation, both the vehicle and the concentration of the allergen are involved.

The optimal vehicle for most corticosteroids is yet to be found. Either ethanol or petrolatum is recommended for tixocortol pivalate and budesonide since studies have shown equivalent patch-test results with either vehicle.3,21 For Hc-17-B, however, only ethanol is recommended because Hc-17-B in petrolatum penetrates to a lesser degree18 and because fewer positive reactions have been seen when parallel testing has been undertaken. The ethanol preparation must be freshly made every 6 to 8 weeks because Hc-17-B degrades spontaneously to hydrocortisone-21-butyrate when stored in ethanol. Ethanol is considered the vehicle of choice for most corticosteroids because penetration is enhanced when ethanol is used instead of petrolatum.3,21,24-26

Another concern is the optimal patch-test concentration, which has not been worked out scientifically for most corticosteroids (ie, by patch-testing consecutive dermatitis patients with specific corticosteroids in serial dilutions). A high patch-test concentration of a potent corticosteroid may yield a negative test result on an early reading occasion whereas a low concentration may yield a positive test result.27 This can be explained by the antiinflammatory action of the corticosteroid itself, which influences patch-test results at early readings (when the antiinflammatory effect prevails), leading to a false-negative test result if the antiinflammatory action predominates over the elicitation of the allergy test eczema.27 This paradox is a unique feature when patch testing is done with some potent corticosteroids. Actually, this phenomenon has been demonstrated in European comparative studies, in which lower concentrations detected more allergic patients than did higher concentrations; therefore, budesonide 0.01% in petrolatum and tixocortol pivalate 0.1% in petrolatum are included in the European Standard series.28-30 In certain cases, however, higher concentrations may be needed if the standard concentration yields a negative result and there is a strong suspicion of contact allergy to these corticosteroids.27 Most other corticosteroids have been tested at 1.0%, and this concentration is still used when testing with Hc-17-B and the majority of corticosteroids.

Another phenomenon that is related to the paradox concerns the “edge effect,”27 which is a positive test reaction in the shape of a ring just outside the patch-test site and a negative reaction where the patch chamber has been placed. The edge effect can be seen at early readings, when high concentrations of potent corticosteroids such as budesonide are tested. This must be interpreted as a negative test result27,31,32 because an eczematous reaction confined to the periphery just outside the test area does not meet the minimal criterion of an allergic patch-test reaction. However, if one also reads the test on a later occasion (day 6 or 7), the test result usually will be positive. Testing with a substantially lower concentration than the one giving the edge effect may yield a positive test result on the early reading occasion. These seemingly contradictory features can also be explained by the interaction of the factors of significance for the patch-test reaction, namely, the degree of individual patch-test reactivity, the temporal dose-response for the antiinflammatory action of the corticosteroid, and the spreading of the test substance.27

A dermatitis patient should be patch-tested also with the different corticosteroids used by that patient (ie, the pure corticosteroid in an appropriate vehicle and concentration). For example, in the United Kingdom, betamethasone valerate and clobetasol propionate are widely used, and patients sensitized to them are not identified with the markers for groups A and B.33 Once a patient has reacted to a screening marker or to a separate corticosteroid, he or she should be tested with an extended corticosteroid series34 containing at least the corticosteroids that are available in that country35 (so as not to miss other contact allergies and to detect cross-reactions), so that further treatment and appropriate information regarding local and systemic therapy may be given. Again, however, the concentrations and vehicles for many of these other corticosteroids have not been extensively investigated, and because there are differences in reactivity among patients, patients will occasionally test negatively to these additional corticosteroids albeit they are allergic to them. For example, patients who are allergic to tixocortol pivalate should refrain from using hydrocortisone even if the test result from hydrocortisone is negative, and patients who are sensitized to budesonide should refrain from using Hc-17-B even if the test result for Hc-17-B is negative. The above-mentioned kind of testing also pertains to patients with corticosteroid-treated asthma/rhinitis and to patients who have taken systemic corticosteroids, in case a corticosteroid type IV allergy is suspected.36,37

Back to Top | Article Outline

Late Readings

The third issue is the importance of performing late readings, mainly because of intrinsic antiinflammatory properties that may influence the patch-test result. The allergic reaction may be suppressed at early readings, and negative patch-test reactions may be seen despite the patient's being allergic to the particular corticosteroid.27 Therefore, an additional reading on day 6 or 7 has been recommended,20,22,25,38 and the following description of one of our recent patients illustrates this very important point. A 50-year-old woman who worked on a restaurant staff had been suffering from what she strongly suspected was a work-related hand dermatitis for a year. She had used a cream containing Hc-17-B daily during the previous year. Patch tests with a standard series containing the three aforementioned corticosteroid markers and with a corticosteroid series were performed. She reacted only to budesonide and only on day 7 (not on day 3). Budesonide cross-reacts with Hc-17-B and seems to be a better marker for Hc-17-B allergy than is Hc-17-B itself, tested at 1.0% in ethanol. After she stopped using the cream containing Hc-17-B and after treatment with another corticosteroid that did not cross-react with budesonide or Hc-17-B, her condition cleared within a month, and she has not had any lesions since.

A Swedish study was the first to investigate the importance of consistent late readings in consecutive dermatitis patients being routinely patch-tested with corticosteroids. Thirty percent of the cases of contact allergy to corticosteroids would have been missed had not readings on day 7 (late readings) been performed. Since then, this phenomenon has been shown in other studies.28,29

Back to Top | Article Outline

References

1. Lauerma AI. Screening for corticosteroid contact sensitivity. Comparison of tixocortol pivalate, hydrocortisone-17-butyrate and hydrocortisone. Contact Dermatitis 1991;24:123-30.
2. Burden AD, Beck MH. Contact hypersensitivity to topical corticosteroids. Br J Dermatol 1992;127:497-500.
3. Dooms-Goossens A, Morren M. Results of routine patch testing with corticosteroid series in 2073 patients. Contact Dermatitis 1992;26:182-91.
4. Lutz ME, el-Azhary RA, Gibson LE, et al. Contact hypersensitivity to tixocortol pivalate. J Am Acad Dermatol 1998;38:691-5.
5. Rietschel RL. Patch testing for corticosteroid allergy in the United States. Arch Dermatol 1995;131:91-2.
6. Reitamo S, Lauerma AI, Stubb S, et al. Delayed hypersensitivity to topical corticosteroids. J Am Acad Dermatol 1986;14:582-9.
7. Guin JD. Contact sensitivity to topical corticosteroids. J Am Acad Dermatol 1984;10:773-82.
8. Venning VA. Fluticasone propionate sensitivity in a patient with contact allergy to multiple corticosteroids. Contact Dermatitis 1995;33:48-9.
9. Hayakawa R, Suzuki M, Ukei C, et al. A case of budesonide contact allergy. Contact Dermatitis 1992;26:128-9.
10. Hayakawa R, Matsunaga K, Suzuki M, et al. Allergic contact dermatitis due to budesonide. Contact Dermatitis 1991;24:136-7.
11. Hayakawa R, Matsunaga K, Suzuki M, Hosokawa K. Contact dermatitis from amcinonide. Contact Dermatitis 1987;16:48-9.
12. Hayakawa R, Matsunaga K, Ukei C, Hosokawa K. Allergic contact dermatitis from amcinonide. Contact Dermatitis 1985;12:213-4.
13. Sasaki E, Shinya M, Fujioka M, et al. Contact dermatitis due to amcinonide. Contact Dermatitis 1988;18:61-2.
14. Miranda-Romero A, Sánchez-Sambucety P, et al. Genital oedema from contact allergy to prednicarbate. Contact Dermatitis 1998; 38:228-9.
15. Stingeni L, Caraffini S, Assalve D, et al. Erythema-multiforme-like contact dermatitis from budesonide. Contact Dermatitis 1996;34: 154-5.
16. Isaksson M, Persson LM. Contact allergy to hydrocortisone and systemic dermatitis from prednisolone with tolerance of betamethasone. Am J Contact Dermat 1998;9:136-8.
17. Chew AL, Maibach HI. Multiple corticosteroid orally elicited allergic contact dermatitis in a patient with multiple topical corticosteroid allergic contact dermatitis. Cutis 2000;65:307-11.
18. Lepoittevin JP, Drieghe J, Dooms-Goossens A. Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 1995;131:31-7.
19. Lauerma AI, Tarvainen K, Förström L, et al. Contact hypersensitivity to hydrocortisone-free alcohol in patients with allergic patch test reactions to tixocortol pivalate. Contact Dermatitis 1993;28:10-4.
20. Degreef H, Dooms-Goossens A. The new corticosteroids: are they effective and safe? Dermatol Clin 1993;11:155-60.
21. Gonzalo Garijo MA, Bobadilla Gonzalez P. Cutaneous-mucosal allergic contact reaction due to topical corticosteroids. Allergy 1995;50:833-6.
22. Lauerma AI. Contact hypersensitivity to glucocorticosteroids. Am J Contact Dermat 1992;31:112-32.
23. Reitamo S, Lauerma AI, Förström L. Detection of contact hypersensitivity to topical corticosteroids with hydrocortisone-17butyrate. Contact Dermatitis 1989;21:159-65.
24. Dooms-Goossens A, Verschaeve H, Degreef H, et al. Contact allergy to hydrocortisone and tixocortol pivalate: problems in the detection of corticosteroid sensitivity. Contact Dermatitis 1986;14:94-102.
25. Dooms-Goossens AE, Degreef HJ, Marien KJ, et al. Contact allergy to corticosteroids: a frequently missed diagnosis? J Am Acad Dermatol 1989;21:538-43.
26. Förström L, Lassus A, Salde L, et al. Allergic contact eczema from topical corticosteroids. Contact Dermatitis 1982;8:128-33.
27. Isaksson M, Bruze M, Goossens A, et al. Patch testing with budesonide in serial dilutions: the significance of dose, occlusion time and reading time. Contact Dermatitis 1999;40:24-31.
28. Isaksson M, Andersen KE, Brandão FM, et al. Patch testing with corticosteroid mixes in Europe. Contact Dermatitis 2000;42: 27-35.
29. Isaksson M, Andersen KE, Brandão FM, et al. Patch testing with budesonide in serial dilutions. A multicentre study of the EECDRG. Contact Dermatitis 2000;42:352-4.
30. Isaksson M, Brandão FM, Bruze M, et al. Recommendation to include budesonide and tixocortol pivalate in the European standard series. Contact Dermatitis 2000;43:41-2.
31. Wilkinson DS, Fregert S, Magnusson B, et al. Terminology of contact dermatitis. Acta Derm Venereol 1970;50:287-92.
32. Bruze M, Conde-Salazar L, Goossens A, et al. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. Contact Dermatitis 1999;41:241-50.
33. Sommer S, Wilkinson SM, English JSC, et al. Type-IV hypersensitivity to betamethasone valerate and clobetasol propionate: results of a multicentre study. Br J Dermatol 2002;147:266-9.
34. Goossens A, Matura M, Degreef H. Some new aspects regarding cross-sensitivity. Cutis 2000;65:43-5.
35. Lauerma AI, Reitamo S. Contact allergy to corticosteroids. J Am Acad Dermatol 1993;28:618-22.
36. Isaksson M, Bruze M. Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen. J Am Acad Dermatol 2002;46:880-5.
37. Bircher AJ, Bigliardi P, Zaugg T, et al. Delayed generalized allergic reactions to corticosteroids. Dermatology 2000;200:349-51.
38. Nakajima H, Mohri S, Nagai R. A case of contact dermatitis due to betamethasone valerate. J Dermatol 1986;13:467-70.
©2005American Contact Dermatitis Society, All Right Reserved